Market Cap
US$324.6m
Last Updated
2020/01/21 00:49 UTC
Data Sources
Company Financials +
Executive Summary
IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases.
Rewards
Risk Analysis
Earnings are forecast to decline by an average of -25.5% per year for the next 3 years
+ 1 more risk
Snowflake Analysis
Flawless balance sheet and fair value.
Share Price & News
How has IVERIC bio's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ISEE's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-0.8%
ISEE
1.1%
US Biotechs
1.7%
US Market
1 Year Return
406.0%
ISEE
11.3%
US Biotechs
23.6%
US Market
Return vs Industry: ISEE exceeded the US Biotechs industry which returned 10.9% over the past year.
Return vs Market: ISEE exceeded the US Market which returned 24.7% over the past year.
Shareholder returns
| ISEE | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.8% | 1.1% | 1.7% |
| 30 Day | -9.8% | 0.2% | 3.5% |
| 90 Day | 617.9% | 19.5% | 11.7% |
| 1 Year | 406.0%406.0% | 12.3%11.3% | 26.2%23.6% |
| 3 Year | 50.7%50.7% | 29.2%24.9% | 53.2%43.3% |
| 5 Year | -88.1%-88.1% | 3.7%-1.2% | 75.5%56.1% |
Price Volatility Vs. Market
How volatile is IVERIC bio's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Does IVERIC bio, Inc. (NASDAQ:ISEE) Have A Particularly Volatile Share Price?2 months ago | Simply Wall St
Could The IVERIC bio, Inc. (NASDAQ:ISEE) Ownership Structure Tell Us Something Useful?4 months ago | Simply Wall St
Does IVERIC bio, Inc. (NASDAQ:ISEE) Have A Particularly Volatile Share Price?Valuation
Is IVERIC bio undervalued compared to its fair value and its price relative to the market?
4.44x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ISEE's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ISEE's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ISEE is good value based on its PE Ratio (4.5x) compared to the Biotechs industry average (20.1x).
PE vs Market: ISEE is good value based on its PE Ratio (4.5x) compared to the US market (18.9x).
Price to Earnings Growth Ratio
PEG Ratio: ISEE's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: ISEE is good value based on its PB Ratio (3.2x) compared to the US Biotechs industry average (3.2x).
Next Steps
Future Growth
How is IVERIC bio forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
-25.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ISEE's earnings are forecast to decline over the next 3 years (-25.5% per year).
Earnings vs Market: ISEE's earnings are forecast to decline over the next 3 years (-25.5% per year).
High Growth Earnings: ISEE's earnings are forecast to decline over the next 3 years.
Revenue vs Market: ISEE is forecast to have no revenue next year.
High Growth Revenue: ISEE is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ISEE's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has IVERIC bio performed over the past 5 years?
42.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ISEE has a large one-off gain of $118.1M impacting its September 30 2019 financial results.
Growing Profit Margin: ISEE became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: ISEE has become profitable over the past 5 years, growing earnings by 42.6% per year.
Accelerating Growth: ISEE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ISEE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).
Return on Equity
High ROE: ISEE's Return on Equity (70.1%) is considered outstanding.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is IVERIC bio's financial position?
Financial Position Analysis
Short Term Liabilities: ISEE's short term assets ($97.0M) exceed its short term liabilities ($9.4M).
Long Term Liabilities: ISEE has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ISEE is debt free.
Reducing Debt: ISEE has no debt compared to 5 years ago when its debt to equity ratio was 47.8%.
Debt Coverage: ISEE has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ISEE has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: ISEE has a low level of unsold assets or inventory.
Debt Coverage by Assets: ISEE's debt is not covered by short term assets (assets are -395.8x debt).
Next Steps
Dividend
What is IVERIC bio's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate ISEE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ISEE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ISEE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ISEE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ISEE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of IVERIC bio's salary, the management and board of directors tenure and is there insider trading?
2.6yrs
Average management tenure
CEO
Glenn Sblendorio (63yo)
2.5yrs
Tenure
US$1,411,380
Compensation
Mr. Glenn P. Sblendorio, M.B.A., has been the President of Ophthotech Corporation since February 1, 2017 and has been its Chief Executive Officer since July 1, 2017. Mr. Sblendorio served as Chief Financia ...
CEO Compensation Analysis
Compensation vs Market: Glenn's total compensation ($USD1.41M) is about average for companies of similar size in the US market ($USD1.70M).
Compensation vs Earnings: Glenn's compensation has been consistent with company performance over the past year.
Management Age and Tenure
2.6yrs
Average Tenure
58yo
Average Age
Experienced Management: ISEE's management team is considered experienced (2.9 years average tenure).
Board Age and Tenure
2.3yrs
Average Tenure
63yo
Average Age
Experienced Board: ISEE's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: ISEE insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Executive Officer CEO, President & Director |
| Shares | 62,500 |
| Max Price | US$4.00 |
| Entity | Individual |
| Role | Chief Executive Officer CEO, President & Director |
| Shares | 15,000 |
| Max Price | US$3.12 |
| Entity | Individual |
| Role | Chief Executive Officer CEO, President & Director |
| Shares | 25,000 |
| Max Price | US$1.48 |
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.5%.
Management Team
Glenn Sblendorio (63yo)
CEO, President & Director
- Tenure: 2.5yrs
- Compensation: US$1.41m
David Guyer (59yo)
Executive Chairman
- Tenure: 13yrs
- Compensation: US$1.01m
Samir Patel (58yo)
Co-Founder and Consultant
- Tenure: 13yrs
Kathy Galante
Vice President of Investor Relations & Corporate Communications
Evelyn Harrison
Chief Clinical Operations Officer
- Tenure: 4yrs
- Compensation: US$411.67k
Keith Westby (44yo)
Senior VP & COO
- Tenure: 3yrs
- Compensation: US$674.13k
Amy Sheehan
Senior VP & Chief Human Resources Officer
- Tenure: 2yrs
Dave Carroll (53yo)
Senior VP
- Tenure: 2.8yrs
- Compensation: US$714.44k
Todd Anderman
VP, General Counsel & Corporate Secretary
- Tenure: 2yrs
Abraham Scaria
Chief Scientific Officer
- Tenure: 0.3yrs
Board Members
Glenn Sblendorio (63yo)
CEO, President & Director
- Tenure: 2.5yrs
- Compensation: US$1.41m
Axel Bolte (47yo)
Independent Director
- Tenure: 12.4yrs
- Compensation: US$90.75k
Adrienne Graves (66yo)
Lead Independent Director
- Tenure: 0.3yrs
- Compensation: US$46.58k
David Guyer (59yo)
Executive Chairman
- Tenure: 13yrs
- Compensation: US$1.01m
Cal Roberts (67yo)
Independent Director
- Tenure: 1yrs
David Cheresh
Member of Translational Scientific Advisory Board
Jane Pritchett Henderson (53yo)
Independent Director
- Tenure: 2yrs
- Compensation: US$161.63k
Rakesh Jain (69yo)
Member of Translational Scientific Advisory Board
Company Information
IVERIC bio, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: IVERIC bio, Inc.
- Ticker: ISEE
- Exchange: NasdaqGS
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$324.645m
- Shares outstanding: 47.88m
- Website: https://ivericbio.com
Number of Employees
Location
- IVERIC bio, Inc.
- One Penn Plaza
- 19th Floor
- New York
- New York
- 10119
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ISEE | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Sep 2013 |
| O2T | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Sep 2013 |
Biography
IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD). It is also developing High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitors for the treatment of GA secondary to dry AMD and other age-related retinal diseases, such as wet AMD and idiopathic polypoidal choroidal vasculopathy. The company has a license agreement with the University of Florida Research Foundation (UFRF) and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP); and Best disease and other bestrophinopathies. It also has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach to create AAV gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and STGD1; and to evaluate various AAV gene delivery methods for potential application in the eye. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.Â
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/01/21 00:49 |
| End of Day Share Price | 2020/01/17 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.